spacer
home > > summer 2002 > offering a global service to support clinical trial
PUBLICATIONS


Offering a Global Service to Support Clinical Trial

Speed, quality and continuity of service are essential when it comes to the analysis of samples taken in clinical trials. Pharmaceutical and biotechnology companies require sample turnaround within 24 hours because patients may require further testing or treatment based on laboratory results. In addition to analytical quality, logistics are critical to ensuring rapid shipment and results turnaround, and therefore the location of laboratories is fundamental.

For a Phase I/IIa study involving a limited number of sites, logistics tend not to be as complex as for a multi-site Phase IIb/III study, which are often conducted on a number of continents. Each country will have its own custom regulations and it is essential that a central laboratory understands them and knows the best ways to prevent shipment delays. For a successful Phase IIb/III trial, the location of laboratories is fundamental. For example, it is almost impossible to undertake a study in South Africa which requires rapid sample analysis if the central laboratory is located in Europe or North America.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Daniel Chapple, Business Development Director and Paul Travis, Head of Central Laboratory Services at CentraLabS

Dr Daniel Chapple is Business Development Director of CentraLabS and is responsible for the company's business throughout Europe, Russia, Asia and South Africa.

With a PhD in Biochemistry and Microbiology, Daniel previously lectured in drug discovery and has acted as a Consultant to a number of development companies.

spacer
Dr Daniel Chapple
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement